The cost-effectiveness methodology for immunisation programmes and procurement (CEMIPP) is currently under review, following a report in 2016. A consultation is underway but has required more details in order to achieve good quality input.
This latest report explains that this cost-effectiveness review is part of a drive to ensure budgets are allocated in the most efficient way, giving the greatest benefit. In the 2016 report, changes were recommended around aspects of pricing such as the cost-effectiveness threshold, discount rate and time horizons.
The report has also summarised some of the expected changes in the cost-effective prices for certain vaccines under different combinations of the 2016 report’s recommendations. For example, if the £15k/QALY threshold is adopted, the cost-effective price of the HPV vaccine will be decreased. However, if the £15k/QALY threshold and and unlimited timescale are adopted, the cost-effective price of the HPV vaccine will rise significantly. The case studies in the information linked below give a good sense of the implications of the report, and good insights into how to respond to the consultation.